First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)

Bull Cancer. 2023 Sep 25:S0007-4551(23)00368-5. doi: 10.1016/j.bulcan.2023.08.006. Online ahead of print.NO ABSTRACTPMID:37758567 | DOI:10.1016/j.bulcan.2023.08.006

Source: Bulletin du Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Marie Porte Thomas Pierret Source Type: research